Down-Regulated microRNA-421 Was Associated with the Poor Prognosis of Breast Cancer Patients

Keqian Zhang  
Southwest Hospital, Army Medical University

Tianqi Mao  
Southwest Hospital, Army Medical University

Zhicheng He  
Southwest Hospital, Army Medical University

Xiaojiao Wu  
Southwest Hospital, Army Medical University

Yu Peng  
Southwest Hospital, Army Medical University

Yanrong Chen  
Southwest Hospital, Army Medical University

Yan Dong  
Southwest Hospital, Army Medical University

Zihua Ruan  
Southwest Hospital, Army Medical University

Zhe Wang (✉️ dfgjt5@yeah.net)  
Southwest Hospital, Army Medical University  https://orcid.org/0000-0001-5094-1907

Primary research

Keywords: MicroRNA-421, Breast cancer, Prognosis, Survival

Posted Date: August 17th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-58140/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

**Background:** Breast cancer is one of the most common cancers among females with high morbidity and mortality. MicroRNAs (miRNAs) have been reported to play important roles in the development of cancers. However, the prognostic value of microRNA-421 (miR-421) in breast cancer have not been extensively explored.

**Methods:** Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect the relative expression of miR-421 in breast cancer tissue samples. Relationships between miR-421 expression and clinicopathological factors were analyzed by chi-square test. The effects of several variables on survival status were tested by Kaplan-Meier curve and Cox proportional hazards regression analyses.

**Results:** MiR-421 expression was significantly decreased in breast cancer tissues, compared with adjacent noncancerous tissues ($P$<0.001). Moreover, abnormal miR-421 expression was closely correlated with lymph node metastasis ($P$<0.001), TNM stage ($P$=0.021), and differentiation ($P$=0.044) of breast cancer patients. Kaplan-Meier analysis revealed that patients with low miR-421 expression had a shorter overall survival time than those with high miR-421 expression ($P$=0.001). Furthermore, multivariate analysis demonstrated that miR-421 ($P$=0.014, HR=2.000, 95%CI: 1.149-3.480) was an independent prognostic indicator in breast cancer patients, as well as lymph node metastasis ($P$=0.016, HR=1.987, 95%CI: 1.137-3.474).

**Conclusion:** The reduced expression of miR-421 may predict the poor prognosis of breast cancer and miR-421 may be involved in the progression of breast cancer.

Background

Breast cancer is the major cause of cancer-related mortality among females worldwide [1] and it is recognized to be a heterogeneous disease with different outcomes and responses to treatment [2]. Currently, numbers of potential risk factors in breast cancer have been identified, such as obesity, lack of physical exercise, alcohol consumption, hormone replacement therapy, using oral contraceptives, ever-breastfeeding, and genetic factors [3-5]. Despite many advances in tumor diagnostic and therapeutic strategies, the prevention and therapy of breast cancer remains a major public health concern [6]. Non-estrogen receptor (ER)-, non-progesterone receptor (PR)-, or non-human epidermal growth factor receptor 2 (Her2, triple negative)-expressing breast cancer patients are not sensitive response to hormonal therapy with Her2-targeted agents. This category of patients often display a inferior clinical outcome due to disease recurrence and distant metastasis [7-9]. Thus, it is urgently required to search for and identify powerful biomarkers to predict the clinical outcome and develop more promising treatment strategies to effectively control aggressive breast cancer.

microRNAs (miRNAs) are a series of short single-stranded RNA molecules and act as post-transcriptional regulators of gene expression by binding 3’-untranslated region (3’UTR) of target mRNA, resulting in an inhibition of translation or degradation of mRNA [10]. MiRNAs are reported to be involved in multiple
biological processes, including cell proliferation, migration, apoptosis, and differentiation [11]. Increasing evidences have proved that dysregulation of miRNA expression is observed in various human cancers, certainly including breast cancer [12]. Furthermore, miRNAs have recently been demonstrated to function as both oncogenes and suppresses of tumor progression [13]. However, the aberrant expression and prognostic performance of microRNA-421 (miR-421) in breast cancer has not been investigated.

In the present study, we detected the relative expression of miR-421 in breast cancer patients and analyzed the correlation between miR-421 expression and clinicopathological characteristics of breast cancer. We also investigated the correlation of miR-421 expression with the overall survival of breast cancer patients.

**Methods And Materials**

**Study samples**

The study was approved by the Ethic Committee of Southwest Hospital, Army Medical University and all patients had signed the written informed contents before sampling.

A total of 117 breast cancer tissues and paired adjacent noncancerous breast tissues were collected at the Department of Pathology, Southwest Hospital, Army Medical University. All the specimens were diagnosed by two pathologists separately to determine the pathological classification of breast cancer. None of patients recruited in this study had undergone preoperative chemotherapy or radiotherapy. The clinical characteristics of patients were collected, including age, tumor size, lymph node metastasis, TNM stage, differentiation, ER status, PR status and Her-2 status. The fresh tissue samples were immediately frozen in liquid nitrogen after surgical removal and stored at -80°C for RNA extraction.

Then all patients were conducted a 5 year-follow-up for prognosis determination. Breast cancer patients who died from other adverse events were excluded.

**RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)**

Total RNA was extracted from breast cancer tissues and matched noncancerous tissues with TRIZOL reagent (Invitrogen, Karlsruhe, Germany) according to the manufacturer’s recommendations. cDNA was synthesized from total RNA using the Taqman miRNA reverse transcription kit (Applied Biosystem, Foster City, CA). QRT-PCR was performed by using the Applied Biosystems 7500 Sequence Detection system. U6 RNA was used as an endogenous reference for normalizing the expression levels of miR-421. The relative expression levels of miR-421 compared to the normal controls were calculated using the method of 2^(-ΔΔCt). All assays were performed at least in triplicate.

**Statistical analysis**

All data were presented at mean ± SD (standard deviation) or n (%). All statistical analyses were performed using SPSS 18.0 (SPSS software, Chicago, Inc, IL, USA), and graphs were plotted by GraphPad
Prism 5.0 (GraphPad Software, Inc, CA, USA). The continuous variable of statistical differences between two groups were analyzed by Student’s t test. The relationships between miR-421 expression and clinicopathological characteristics were evaluated using chi-square test. Survival curves were plotted using Kaplan-Meier methods and compared with log-rank test. The Cox proportional regression model analysis were applied to evaluate the prognostic significance of miR-421 in breast cancer patients. All tests were two-tailed, and when \( P<0.05 \) was considered to be statistically significant.

**Results**

**Down-regulation of miR-421 expression in breast cancer**

To investigate the role of miR-421 in breast cancer, we detected the relative expression of miR-421 level in 117 breast cancer tissues and matched noncancerous tissues using qRT-PCR. As shown in Figure 1, compared with paired noncancerous tissues, miR-421 expression level was significantly down-regulated in breast cancer tissues (\( P<0.001 \)).

**MiR-421 expression was associated with clinicopathologic features of breast cancer patients**

We also explored the association of miR-421 expression with clinicopathological factors of breast cancer patients, 117 patients were divided into two groups based on the median value (0.56) of miR-421 expression in breast cancer tissues: low miR-421 expression group (n=59) and high miR-421 expression group (n=58). As indicated in Table 1, abnormal miR-421 expression was significantly correlated with lymph node metastasis (\( P=0.000 \)), TNM stage (\( P=0.021 \)), and differentiation (\( P=0.044 \)) of breast cancer patients. Unfortunately, no significant difference was observed between miR-421 expression and other clinicopathologica factors, such as age, tumor size, ER status, PR status, or Her-2 status (all \( P>0.05 \)).

**The prognostic value of miR-421 expression in breast cancer**

To investigate the prognostic significance of miR-421 in breast cancer, Kaplan-Meier method was employed to analyze the relationship of miR-421 with survival time of breast cancer patients. Results showed that patients with low miR-421 expression had a worse overall survival than those with high miR-421 expression (\( P=0.001 \), Figure 2).

Subsequently, we performed univariate and multivariate Cox regression analyses to define the prognosis role of miR-421 in breast cancer with hazard ratio (HR) and 95%CI. In univariate analysis, miR-421 expression (\( P=0.002 \)) and TNM stage (\( P=0.022 \)) were closely related to overall survival (Table 2). Multivariate analysis indicated miR-421 expression (\( P=0.014 \), HR=2.000, 95%CI: 1.149-3.480) was an independent prognostic indicator for breast cancer, together lymph node metastasis (\( P=0.016 \), HR=1.987, 95%CI: 1.137-3.474) (Table 2).

**Discussion**
Breast cancer is the most prevalent malignancy and is also a leading cause of cancer-related deaths among females worldwide. Although there are tremendous advances made in developing multiple treatments, the clinical outcome of breast cancer patients is still unfavorable. It is difficult to coordinate effective treatment strategies for every patient, due to heterogeneity at phenotypic and molecular levels\[^2\]. Therefore, it is of great significance to investigate the underlining molecular mechanisms and identify powerful biomarkers for prediction of prognosis in breast cancer.

Overwhelming evidences have strongly demonstrated that dysregulation of miRNAs is involved in the initiation and development of cancers, which explains the controls of multiple critical functions, such as cancer cell proliferation, migration, and resistance to therapeutic interventions\[^14\]. In recent years, more and more studies indicate that miRNAs are proved to be served as biomarkers in a variety of cancers\[^15-18\]. Fan et al. reported that miR-196a might play an important role in the progression of ovarian carcinoma, and could be acted as an independent prognostic biomarker for ovarian carcinoma\[^19\]. Dong et al. revealed that the decreased expression of miR-124 might be associated with tumor progression and poor prognosis in breast cancer patients\[^20\]. Therefore, it is of great importance to understand the functions of miRNAs and provide new insights on the involved molecules in the development of cancers and novel markers for cancer prognosis, diagnosis and treatment.

\textit{MiR-421}, located on X chromosome, was first implicated in gastric cancer oncogenesis\[^21\]. It has been reported that miR-421 is abnormally expressed in a variety of tumors and is a promising prognostic biomarker in cancers. For instance, Liu et al. found that miR-421 was correlated with lymph node metastasis and prognosis of gastric carcinoma\[^22\]. Jiang et al. also showed that miR-421 might be involved in the early stage of stomach carcinogenesis and could be used as an efficient diagnostic biomarker\[^23\]. In our present study, we focused on the abnormal miR-421 expression in breast cancer tissues, indicating that miR-421 play the important roles in the pathogenesis of breast cancer.

In the present study, we compared miR-421 expression level between breast cancer tissues with matched noncancerous tissues. By qRT-PCR analysis, we found that miR-421 expression was significantly decreased in breast cancer tissues compared with adjacent normal tissues. In addition, the relationship of miR-421 expression with clinicopathological features was also explored. Results showed that down-regulated miR-421 expression was connected to lymph node metastasis, TNM stage and differentiation of breast cancer patients. It indicated that abnormal miR-421 expression might be involved in the progression of breast cancer patients. In a further survival analysis, patients with high miR-421 expression had dramatically longer survival time than those with low miR-421 expression, suggesting the correlation between miR-421 expression and breast cancer clinical outcome. Multivariate analysis revealed that miR-421 was an independent prognostic biomarker for breast cancer patients, as well as lymph node metastasis. Our findings were consistent with previous studies. For example, Pan et al. reported that miR-421 was down-regulated in breast cancer tissues and metastatic cell lines, and was significantly associated with lymph node metastasis, recurrence/metastasis, or pTNM stage\[^24\]. Wang et al. demonstrated that miR-421 was down-regulated in lymph node metastasis group compared with non lymph node metastasis group of breast cancer\[^25\].
Conclusion

In summary, miR-421 expression is significantly down-regulated in breast cancer tissues, and may be associated with the progression of breast cancer. miR-421 may be served as an independent prognostic biomarker of breast cancer. However, further studies should be conducted with larger sample size and longer follow-up time to confirm the clinical application of miR-421 in breast cancer.

List Of Abbreviations

MicroRNAs (miRNAs)

microRNA-421 (miR-421)

Quantitative real-time polymerase chain reaction (qRT-PCR)

Non-estrogen receptor (ER)

Non-progesterone receptor (PR)

3’-untranslated region (3’UTR)

hazard ratio (HR)

Declarations

Ethics approval and consent to participate

This study was supported by the Ethics Committee of Southwest Hospital, Army Medical University and also has been carried out in accordance with the World Medical Association Declaration of Helsinki.

Consent for publication

The subjects had been informed the objective. Certainly, written consents were signed by every subject in this study.

Data availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions
K.Z. design of the work; T.M., Z.H. the acquisition, analysis, X.W., Y.P. interpretation of data; Y.C., Y.D. the creation of new software used in the work; Z.R., Z.W. have drafted the work or substantively revised it. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References

1. Siegel R, Ma J, Zou Z, Jemal A: **Cancer statistics, 2014. CA: a cancer journal for clinicians** 2014, 64(1):9-29.

2. Ng CK, Pemberton HN, Reis-Filho JS: **Breast cancer intratumor genetic heterogeneity: causes and implications. Expert review of anticancer therapy** 2012, 12(8):1021-1032.

3. Shah R, Rosso K, Nathanson SD: **Pathogenesis, prevention, diagnosis and treatment of breast cancer. World journal of clinical oncolgy** 2014, 5(3):283-298.

4. Brody JG, Rudel RA, Michels KB, Moysich KB, Bernstein L, Attfield KR, Gray S: **Environmental pollutants, diet, physical activity, body size, and breast cancer: where do we stand in research to identify opportunities for prevention? Cancer** 2007, 109(12 Suppl):2627-2634.

5. Anothaisintawee T, Wiratkapun C, LerdSitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, Hirunpat S, Woodtichartpreecha P, Boonlikit S, Teerawattananon Y et al: **Risk factors of breast cancer: a systematic review and meta-analysis. Asia-Pacific journal of public health** 2013, 25(5):368-387.

6. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al: **Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology** 2009, 27(8):1160-1167.

7. Bartolotti M, Franceschi E, Brandes AA: **Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. Future Oncol** 2013, 9(11):1653-1664.

8. Blanco E, Ferrari M: **Emerging nanotherapeutic strategies in breast cancer. Breast** 2014, 23(1):10-18.

9. Williams C, Lin CY: **Oestrogen receptors in breast cancer: basic mechanisms and clinical implications. Ecancermedicalscience** 2013, 7:370.

10. Guo H, Ingolia NT, Weissman JS, Bartel DP: **Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature** 2010, 466(7308):835-840.

11. Kasinski AL, Slack FJ: **Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nature reviews Cancer** 2011, 11(12):849-864.

12. Kang H, Kim C, Lee H, Rho JG, Seo JW, Nam JW, Song WK, Nam SW, Kim W, Lee EK: **Downregulation of microRNA-362-3p and microRNA-329 promotes tumor progression in human breast cancer. Cell death and differentiation** 2016, 23(3):484-495.
13. Wang W, Luo YP: MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential. *Journal of Zhejiang University Science B* 2015, 16(1):18-31.

14. Lujambio A, Lowe SW: The microcosmos of cancer. *Nature* 2012, 482(7385):347-355.

15. Iorio MV, Croce CM: MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. *EMBO molecular medicine* 2012, 4(3):143-159.

16. Hayes J, Peruzzi PP, Lawler S: MicroRNAs in cancer: biomarkers, functions and therapy. *Trends in molecular medicine* 2014, 20(8):460-469.

17. Motawi TK, Rizk SM, Ibrahim TM, Ibrahim IA: Circulating microRNAs, miR-92a, miR-100 and miR-143, as non-invasive biomarkers for bladder cancer diagnosis. *Cell biochemistry and function* 2016, 34(3):142-148.

18. Saldanha G, Elshaw S, Sachs P, Alharbi H, Shah P, Jothi A, Pringle JH: microRNA-10b is a prognostic biomarker for melanoma. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc* 2016, 29(2):112-121.

19. Fan Y, Fan J, Huang L, Ye M, Huang Z, Wang Y, Li Q, Huang J: Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma. *International journal of clinical and experimental pathology* 2015, 8(4):4132-4137.

20. Dong LL, Chen LM, Wang WM, Zhang LM: Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer. *Diagnostic pathology* 2015, 10:45.

21. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, Wang Y: Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. *Journal of gastroenterology and hepatology* 2009, 24(4):652-657.

22. Liu H, Gao Y, Song D, Liu T, Feng Y: Correlation between microRNA-421 expression level and prognosis of gastric cancer. *International journal of clinical and experimental pathology* 2015, 8(11):15128-15132.

23. Jiang Z, Guo J, Xiao B, Miao Y, Huang R, Li D, Zhang Y: Increased expression of miR-421 in human gastric carcinoma and its clinical association. *Journal of gastroenterology* 2010, 45(1):17-23.

24. Pan Y, Jiao G, Wang C, Yang J, Yang W: MicroRNA-421 inhibits breast cancer metastasis by targeting metastasis associated 1. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 2016, 83:1398-1406.

25. Wang B, Li J, Sun M, Sun L, Zhang X: miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. *IUBMB life* 2014, 66(5):371-377.

**Tables**

Table 1.
The relationships between *miR-421* expression and clinicopathological factors

| Factors                        | Cases (n=117) | *MiR-421* expression | $\chi^2$ | P-value |
|-------------------------------|---------------|----------------------|----------|---------|
|                               |               | Low (n=59)           | High (n=58) |         |
| **Age (years)**               |               |                      |          |         |
| <50                           | 36            | 19                   | 17       | 0.115   | 0.735   |
| ≥50                           | 81            | 40                   | 41       |         |         |
| **Tumor size (cm)**           |               |                      |          |         |
| <2                            | 76            | 36                   | 40       | 0.812   | 0.368   |
| ≥2                            | 41            | 23                   | 18       |         |         |
| **Lymph node metastasis**     |               |                      |          |         |
| Absent                        | 87            | 35                   | 52       | 14.114  | <0.001  |
| Present                       | 30            | 24                   | 6        |         |         |
| **TNM stage**                 |               |                      |          |         |
| Ⅰ-Ⅱ                          | 79            | 34                   | 45       | 5.313   | 0.021   |
| Ⅲ-Ⅳ                          | 38            | 25                   | 13       |         |         |
| **Differentiation**           |               |                      |          |         |
| Well and moderate             | 85            | 38                   | 47       | 4.070   | 0.044   |
| Poor                          | 32            | 21                   | 11       |         |         |
| **ER status**                 |               |                      |          |         |
| Positive                      | 56            | 26                   | 30       | 0.687   | 0.407   |
| Negative                      | 61            | 33                   | 28       |         |         |
| **PR status**                 |               |                      |          |         |
| Positive                      | 74            | 38                   | 36       | 0.069   | 0.793   |
| Negative                      | 43            | 21                   | 22       |         |         |
| **Her2 status**               |               |                      |          |         |
| Negative                      | 84            | 41                   | 43       | 0.312   | 0.577   |
| Positive                      | 33            | 18                   | 15       |         |         |

ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor
Table 2.

The univariate and multivariate analyses for overall survival in breast cancer patients

| Features                  | Univariate analysis |           | Multivariate analysis |           |
|---------------------------|---------------------|-----------|-----------------------|-----------|
|                           | HR (95%CI)          | P-value   | HR (95%CI)            | P-value   |
| Age                       | 1.354 (0.787-2.327) | 0.273     | -                     | -         |
| Tumor size                | 1.152 (0.674-1.968) | 0.604     | -                     | -         |
| Lymph node metastasis     | 2.444 (1.429-4.181) | 0.001     | 1.987 (1.137-3.474)   | 0.016     |
| TNM stage                 | 1.847 (1.095-3.117) | 0.022     | -                     | -         |
| Differentiation           | 1.560 (0.901-2.701) | 0.112     | -                     | -         |
| ER status                 | 0.914 (0.546-1.530) | 0.732     | -                     | -         |
| PR status                 | 1.107 (0.651-1.882) | 0.707     | -                     | -         |
| Her-2 status              | 1.217 (0.698-2.124) | 0.488     | -                     | -         |
| MiR-421 expression        | 2.351 (1.381-4.004) | 0.002     | 2.000 (1.149-3.480)   | 0.014     |

**Figures**
The relative expression of miR-421 was detected using quantitative reserve transcription polymerase chain reaction in breast cancer tissues (qRT-PCR). Results showed that miR-421 expression was significantly reduced in breast cancer tissues compared with adjacent noncancerous tissues (P<0.001).
The Kaplan-Meier analysis revealed that low miR-421 expression was associated with shorter overall survival of breast cancer patients (log-rank test, P=0.001).

Figure 2